56,861 Shares in Pacific Biosciences of California, Inc. (NASDAQ:PACB) Bought by XTX Topco Ltd

XTX Topco Ltd bought a new position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 56,861 shares of the biotechnology company’s stock, valued at approximately $97,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atom Investors LP bought a new position in shares of Pacific Biosciences of California during the third quarter worth about $30,000. Water Island Capital LLC increased its position in Pacific Biosciences of California by 91.1% during the 2nd quarter. Water Island Capital LLC now owns 20,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 9,537 shares during the period. Atria Investments Inc raised its holdings in Pacific Biosciences of California by 85.7% during the 3rd quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 10,138 shares during the last quarter. Centiva Capital LP acquired a new position in shares of Pacific Biosciences of California in the 3rd quarter worth approximately $40,000. Finally, Ballentine Partners LLC acquired a new position in shares of Pacific Biosciences of California in the 3rd quarter worth approximately $43,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PACB shares. Piper Sandler lifted their target price on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a research note on Monday, November 11th. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research report on Monday, November 11th. Scotiabank dropped their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research note on Monday, November 11th. Finally, StockNews.com raised Pacific Biosciences of California to a “sell” rating in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $2.95.

Pacific Biosciences of California Trading Up 2.1 %

NASDAQ PACB opened at $1.97 on Friday. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97. Pacific Biosciences of California, Inc. has a 52 week low of $1.16 and a 52 week high of $10.65. The business has a 50 day moving average price of $2.00 and a 200-day moving average price of $1.77. The company has a market cap of $539.51 million, a price-to-earnings ratio of -1.35 and a beta of 1.95.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.